JW Therapeutics

What JW Therapeutics does

JW Therapeutics (药明巨诺, HKEx: 2126) is a Shanghai-based, publicly traded clinical-stage and commercial-stage biopharmaceutical company founded in 2016 as a joint venture between WuXi AppTec and Juno Therapeutics (now a Bristol Myers Squibb subsidiary, the company's largest shareholder). The company develops, manufactures, and commercializes cell immunotherapy products, principally autologous anti-CD19 CAR-T therapies. Its lead commercial product is Carteyva (relmacabtagene autoleucel injection / relma-cel), which is China's first Category 1 biologics CAR-T approval and is currently marketed for three relapsed/refractory B-cell non-Hodgkin lymphoma indications (r/r LBCL, r/r FL, and r/r MCL), with Macau approval secured in June 2025.

The company's core technology stack comprises (i) a CAR-T platform with proprietary CD19/CD20 dual-targeting (JWCAR201) and armored, persistence-enhanced constructs (JWCAR239); (ii) a self-developed lentiviral vector production system (sLVV / JWLV011) intended to replace imported vectors and reduce per-batch cost; (iii) a 19-node COI/COC traceability system integrated with MES, SAP, and LIMS for real-time GMP quality monitoring; and (iv) a manufacturing footprint anchored by a ~12,000 sqm Suzhou commercial facility designed for up to 3,000 autologous batches per year, plus a ~2,500 sqm Zhangjiang R&D center in Shanghai. Beyond hematologic oncology, the pipeline targets solid tumors (MAGE-A4 TCR-T JWTCR001, GPC3 CAR-T JWATM204, JWATM214) and autoimmune diseases (SLE, systemic sclerosis) using relma-cel as a CD19 B-cell depletion platform.

Commercially, JW Therapeutics operates an enterprise field-sales model that distributes through a published, updatable network of trained and certified medical institutions authorized to administer Carteyva, with per-infusion pricing between CNY 999,000 and 1.3 million. Revenue is generated via (a) one-time product sales of Carteyva, supported by 100+ Inclusive Supplementary Health Insurance plans and inclusion (effective January 2026) in the national NHSA Commercial Health Insurance Innovative Drug Directory; and (b) technology licensing and milestone payments — including an sLVV license to Juno (up to USD 10 million) and an expanded TCR-T collaboration with Regeneron (up to USD 50 million in milestones), with JW retaining Greater China commercialization rights. Headcount is reported at 251-500, with operations concentrated in Shanghai, Suzhou, and Beijing.

Name

JW Therapeutics

Legal name

JW Therapeutics (Shanghai) Co., Ltd. (上海药明巨诺生物科技有限公司)

Website

https://jwtherapeutics.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

251–500 employees

Short description

JW Therapeutics (药明巨诺, HKEx: 2126) is a Shanghai-headquartered, publicly traded cell immunotherapy company that develops, manufactures, and commercializes autologous CAR-T therapies, with Carteyva approved in China and Macau for three relapsed/refractory B-cell non-Hodgkin lymphoma indications and a broader pipeline in solid tumors and autoimmune diseases.

Ownership category

akta.pro rank

Product category

Cell Immunotherapy (CAR-T)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• CAR-T cell therapy
• Cell immunotherapy
• Autologous cell therapy
• Lentiviral vector manufacturing
• Oncology biologics

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. CAR-T Product Sales (Carteyva/Bienaida): Revenue from commercial sales of relmacabtagene autoleucel injection (Carteyva/倍诺达) for approved oncology indications including r/r LBCL, r/r FL, and r/r MCL, priced at CNY 999,000 to CNY 1.3 million per infusion
2. Technology Licensing and Milestone Payments: Revenue from licensing proprietary CAR-T manufacturing processes (Drug Product Process, Lentiviral Vector Manufacturing Process) to global partners such as Regeneron, generating milestone payments up to USD 50 million and sLVV licensing fees up to USD 10 million from Juno Therapeutics

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

JW Therapeutics develops, manufactures, and commercializes autologous CAR-T cell immunotherapy products. Its flagship product Carteyva (relmacabtagene autoleucel injection) is approved in China for three non-Hodgkin lymphoma indications (r/r LBCL, r/r FL, r/r MCL) and priced at CNY 999,000 to CNY 1.3 million per infusion. The company also licenses its proprietary manufacturing processes (including self-developed lentiviral vector technology) to global partners such as Juno Therapeutics/BMS.

Product overview

JW Therapeutics (港交所代码:2126) is an independent innovative biotechnology company founded in 2016 through a collaboration between WuXi AppTec and Juno Therapeutics, focusing on developing, manufacturing, and commercializing cell immunotherapy products. The company operates an integrated platform spanning scientific discovery, process development, manufacturing, quality management, and clinical application. The core product portfolio centers on CAR-T cell therapies led by Carteyva® (Relmacabtagene Autoleucel Injection / relma-cel), China's first Category 1 biologics CAR-T product approved for three non-Hodgkin lymphoma indications. The pipeline includes next-generation CAR-T products (JWCAR201, JWCAR239) with dual CD19/CD20 targeting and armored module technologies, BCMA-targeted JWCAR129, solid tumor programs (JWTCR001 for MAGE-A4 TCR-T, JWATM204, JWATM214), and autoimmune disease applications (SLE, SSc). Manufacturing infrastructure includes a Suzhou commercial production base with ~3,000 patient capacity annually and a Zhangjiang R&D center for process development. The company maintains global partnerships with Regeneron for TCR-T development and Juno Therapeutics/BMS for technology licensing.

Differentiator

Problem solved

Functional benefit

Brands

• 倍诺达® (Carteyva®): Relmacabtagene autoleucel injection (relma-cel) - the company's first approved CAR-T product for hematologic malignancies including LBCL, FL, and MCL
• onCARlytics
• COI/COC System

Products and services

• Carteyva® (Relmacabtagene Autoleucel Injection / Relma-cel) Autologous anti-CD19 CAR-T cell immunotherapy product for adult patients with relapsed or refractory large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma; commercial pricing CNY 999,000 to CNY 1.3 million per infusion.
• JWCAR201 Autologous dual-targeting CD19/CD20 CAR-T product designed to prevent antigen escape and manufactured using a rapid, automated platform; in clinical trials for relapsed/refractory diffuse large B-cell lymphoma.
• JWCAR239 Enhanced autologous anti-CD19/CD20 dual-targeting CAR-T cell therapy incorporating armored modules designed to promote persistence, augment co-stimulation, and provide immune shielding, in clinical trials for relapsed/refractory B-cell non-Hodgkin lymphoma.
• JWCAR129 (BCMA-targeted CAR-T) BCMA-targeted CAR-T cell therapy candidate based on Juno's orvacabtagene autoleucel (orva-cel) construct, in preclinical and clinical development for multiple myeloma.
• JWTCR001 (MAGE-A4 TCR-T 2.0) Next-generation MAGE-A4 TCR-T cell therapy featuring CTBR12 switch receptor technology that converts TGF-β inhibition signals into activation signals, targeting solid tumors including esophageal squamous cell carcinoma, synovial sarcoma, ovarian cancer, and squamous NSCLC; in Phase I MARVEL trial in China.
• JWATM204 (GPC3-targeted CAR-T) Autologous CAR-T product targeting GPC3 (glypican-3) for hepatocellular carcinoma and solid tumors, based on Eureka's CAR constructs, in a Phase I investigator-initiated trial in China.
• JWATM214 CAR-T product for solid tumors developed using Lyell technology, in preclinical and early clinical development.
• Relma-cel for Systemic Lupus Erythematosus (SLE) CD19 CAR-T therapy (relmacabtagene autoleucel) being developed for autoimmune indications including SLE and lupus nephritis; Phase 1 data showed a 100% SRI-4 response rate.
• Relma-cel for Systemic Sclerosis (SSc) CD19 CAR-T therapy (relmacabtagene autoleucel) for progressive diffuse cutaneous systemic sclerosis; Phase 1 trial demonstrated deep B-cell depletion and was presented at SSWC 2026 as a Late-Breaking abstract.

Quantifiable outcome

• 100% SRI-4 response rate in SLE Phase 1 trial (12/12 patients)
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• ImugenecoreStrategic or Co-development Partner · 28 November 2025Collaboration to evaluate combination of Imugene's CF33-CD19 oncolytic virus (onCARlytics) with JW's Carteyva CD19 CAR-T therapy for refractory solid tumors. Includes preclinical studies and Phase 1 trial in China, developing novel 'mark and kill' treatment strategy.
• Regeneron PharmaceuticalscoreStrategic or Co-development Partner · 30 October 2025Expanded strategic collaboration for TCR-T cell therapy development. JW Therapeutics receives up to USD 50 million in milestone payments for MAGE-A4 product development. Regeneron grants non-exclusive global license to JW Therapeutics' Drug Product Process and option for Lentiviral Vector Manufacturing Process. JW Therapeutics retains Greater China development and commercialization rights.
• Regeneron Pharmaceuticals (via 2seventy Bio acquisition)coreStrategic or Co-development Partner · 30 October 2025Strategic alliance for MAGE-A4 TCR.CTBR12 (JWTCR001) development in China, Hong Kong, and Macau. JWTCR001 uses proprietary CTBR12 switch receptor technology to convert TGF-beta suppression into activation signal for enhanced antitumor activity in solid tumors.
• Juno Therapeutics (Bristol Myers Squibb)coreOEM/ Whitelabel/ Licensing Partner · 14 April 2025sLVV (self-developed lentiviral vector) manufacturing technology licensing agreement. JW Therapeutics grants Juno non-exclusive license to JW sLVV manufacturing process for CAR-T production. Total consideration up to USD 10 million. Juno is BMS's CAR-T subsidiary and JW Therapeutics' largest shareholder.
• WuXi AppTec (药明康德)coreStrategic or Co-development Partner · 1 January 2016JW Therapeutics was co-founded in 2016 by WuXi AppTec and Juno Therapeutics, combining global cell therapy expertise with Chinese pharmaceutical development and manufacturing capabilities.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Emerging players

• Cellectis: Clinical-stage gene and cell therapy company developing allogeneic CAR-T and TCR-T platforms; competes in JW's solid tumor and hematologic cell therapy development space across multiple modalities.
• Allogene Therapeutics: US-listed allogeneic CAR-T developer whose off-the-shelf approach could disrupt the autologous CAR-T economics on which JW's Carteyva depends; competitor in the broader hematologic cell therapy market.
• Eureka Therapeutics: US/CN clinical-stage biotech developing solid-tumor CAR-T constructs (including GPC3 targeting) - JW's JWATM204 program is based on Eureka's CAR constructs, making Eureka a technology licensor and direct pipeline peer.

Direct peers

• Carsgen Therapeutics: Hong Kong-listed Chinese CAR-T developer of zevorcabtagene autoleucel (zev-cel, CT041), approved for multiple myeloma and operating in CAR-T cell therapy with overlapping hematologic malignancy indications.
• Legend Biotech: Develops Carvykti, a BCMA-directed CAR-T co-developed with Johnson & Johnson for multiple myeloma - a direct BCMA-targeting CAR-T peer overlapping with JW's JWCAR129 pipeline asset.
• Fosun Kite Biotechnology: Chinese JV between Fosun Pharma and Kite (Gilead) that localizes and commercializes Yescarta CAR-T therapy in China for B-cell NHL - directly competes with Carteyva in the same approved indications and hospital channel.
• Gracell Biotechnologies: Chinese allogeneic CAR-T developer acquired by AstraZeneca, focused on B-cell malignancies and autoimmune - directly competes in next-generation cell therapy formats targeting the same Chinese patient population.

Broad incumbents

• Bristol Myers Squibb: Global CAR-T leader through its Juno Therapeutics subsidiary (Brexucabtagene Autoleucel / Breyanzi / Abecma) and JW Therapeutics' largest shareholder and technology-licensing partner - defines the competitive and governance landscape for JW.
• Novartis: Develops and commercializes Kymriah, the first FDA-approved CAR-T therapy; a global incumbent in the same CAR-T modality that JW Therapeutics targets, providing global competitive and regulatory benchmarks.
• Gilead Sciences (Kite): Markets Yescarta and Tecartus CAR-T therapies globally via its Kite subsidiary, including in China through the Fosun Kite JV - establishes the competitive CAR-T benchmark JW must beat on cost, manufacturing, and indication breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/jw-therapeutics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JW Therapeutics